CD38 and mature T-cell and NK-cell non-Hodgkin lymphoma: As CD38 is expressed on the surface of numerous immune cells, including those of B-lymphocyte, T-lymphocyte, and myeloid origin [8], there is scientific rationale for the use of CD38 therapies in other hematologic malignancies including Hodgkin’s lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), and peripheral T-cell lymphoma (PTCL) [50,51].